[Primary Antibody]

TCF7L2 Recombinant Rabbit mAb

- DATASHEET -

Host: Rabbit Clonality: Recombinant

CloneNo.: 2C2 SWISS: Q9NQB0

Isotype: IgG

GeneID: 6934 Target: TCF7L2

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: TCF-4, transcription factor 4, is a basic helix-turn-helix transcription factor. This protein recognizes an Ephrussi-box ('E-box') binding site ('CANNTG') - a motif first identified in immunoglobulin enhancers. The gene for TCF-4 is expressed predominantly in pre-B-cells, although it is found in other tissues as well. Multiple alternatively spliced transcript variants that encode different proteins have been described. TCF4, also known as TCF7L2, is expressed widely during development. Gene targeting study indicates that it is required to maintain the crypt stem cells of the small intestine. TCF4 has many different splicing isoforms and they are expressed differentially in tissues and in cancers of different stages. Studies also indicate that variant of the TCF4 gene confers an increased risk of type 2 diabetes.

- VALIDATION IMAGES



25 ug total protein per lane of various lysates (see on figure) probed with TCF7L2 monoclonal antibody, unconjugated (bsm-52543R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with TCF7L2 Monoclonal Antibody, Unconjugated (bsm-52543R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Glioma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with TCF7L2 Monoclonal Antibody, Unconjugated (bsm-52543R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.



4% Paraformaldehyde-fixed HepG2 (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (TCF7L2) monoclonal Antibody, unconjugated (bsm-52543R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-60295G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to



Blank control (black line) :HepG2. Primary Antibody (green line): Mouse Anti-TCF7L2 antibody (bsm-52543R) Dilution:1:50; Secondary Antibody (white blue line) : Goat anti-Mouse IgG-AF488 Dilution: 0.5ug/Test. Isotype control (orange line) : Normal Rabbit IgG Protocol The cells were fixed with 4% PFA (10min at room Applications: WB (1:500-2000) IHC-P (1:50-200) IHC-F (1:50-200) IF (1:50-200) Flow-Cyt (1:50-100) ICC/IF (1:50-200)

Reactivity: Human, Mouse, Rat

Predicted MW.: ^{68 kDa}

Subcellular Location: Nucleus temperature) and then permeabilized with 90% ice-cold methanol for 20 min at -20°C, The cells were then incubated in 5%BSA to block nonspecific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

- SELECTED CITATIONS -

• [IF=10.75] Tao Zhang. et al. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR. INT J BIOL SCI. 2022; 18(11): 4560–4577 IF ;Human. 35864968